Xarelto Internal Bleeding Lawyers

In Xarelto internal bleeding lawsuits, our attorneys can support clients from St. Louis, Metro-East Illinois and surrounding areas as they pursue substantial compensation for medical expenses, suffering, and other damages. We believe that the makers of Xarelto knew of the risk of serious or fatal internal bleeding, but failed to provide adequate warning of these dangers to doctors and patients.

Xarelto Internal Bleeding Side Effects

Xarelto (rivaroxaban) is a blood thinner prescribed to patients with atrial fibrillation or who have recently undergone knee replacement surgery to prevent blood clots which could cause heart attack or stroke. Xarelto was introduced in 2011 and was heavily marketed as a superior alternative to Coumadin (warfarin), the go-to anticoagulant for decades, based on claims that patients taking Xarelto did not require blood monitoring to ensure proper dosing.

Unfortunately, the truth soon came out as thousands of patients suffered serious or even fatal internal bleeding as a Xarelto side effect. When a patient taking warfarin develops internal bleeding, a doctor can stop the hemorrhage with a timely dose of Vitamin K. There is no such reversal agent for Xarelto internal bleeding. Additionally, multiple studies showed that patients taking Xarelto would be less likely to suffer internal bleeding had their blood been routinely monitored by doctors.

Xarelto Lawsuits

In Xarelto internal bleeding lawsuits, plaintiffs claim that the makers of this drug withheld information about the risk of Xarelto internal bleeding and the lack of a reversal agent to stop this bleeding. These claims are very similar to those made against the makers of Pradaxa, another anticoagulant linked to serious internal bleeding. In 2014, Boehringer Ingelhiem paid out more than $650 to settle Pradaxa lawsuits, and many believe that similar settlements may be upcoming for victims of Xarelto internal bleeding.

Our St. Louis and Metro-East Illinois lawyers are currently forming Xarelto lawsuits based on the following claims:


  • Johnson & Johnson and Bayer failed to warn of the true risk of Xarelto bleeding
  • These drug makers should have alerted the public to the lack of a Xarelto bleeding reversal agent
  • Xarelto was heavily marketed as a safe drug which did not require frequent blood monitoring, which proved to be untrue
  • Xarelto is unreasonably unsafe – a defective and dangerous drug
  • Johnson & Johnson and Bayer should have updated Xarelto warnings and made doctors aware of internal bleeding risks after post-marketing data showed an unreasonably high number of Xarelto internal bleeding injuries and deaths


If you believe you may be entitled to compensation for your suffering and damages resulting from Xarelto internal bleeding, contact us for a free legal consultation at our offices in St. Louis or Metro-East Illinois.